ZA200206879B - Fusion protein having enhanced in vivo erythropoietin activity. - Google Patents

Fusion protein having enhanced in vivo erythropoietin activity.

Info

Publication number
ZA200206879B
ZA200206879B ZA200206879A ZA200206879A ZA200206879B ZA 200206879 B ZA200206879 B ZA 200206879B ZA 200206879 A ZA200206879 A ZA 200206879A ZA 200206879 A ZA200206879 A ZA 200206879A ZA 200206879 B ZA200206879 B ZA 200206879B
Authority
ZA
South Africa
Prior art keywords
fusion protein
epo
enhanced
erythropoietin activity
activity
Prior art date
Application number
ZA200206879A
Other languages
English (en)
Inventor
Bo-Sup Chung
Ki-Wan Kim
Dong-Eok Lee
Myung-Suk Oh
Ji-Sook Park
Original Assignee
Cheil Jedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheil Jedang Corp filed Critical Cheil Jedang Corp
Publication of ZA200206879B publication Critical patent/ZA200206879B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
ZA200206879A 2001-12-03 2002-08-28 Fusion protein having enhanced in vivo erythropoietin activity. ZA200206879B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2001-0075994A KR100467751B1 (ko) 2001-12-03 2001-12-03 생체내 에리스로포이에틴 활성이 증진된 융합단백질

Publications (1)

Publication Number Publication Date
ZA200206879B true ZA200206879B (en) 2003-04-29

Family

ID=36123483

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200206879A ZA200206879B (en) 2001-12-03 2002-08-28 Fusion protein having enhanced in vivo erythropoietin activity.

Country Status (17)

Country Link
US (1) US7091326B2 (fr)
EP (1) EP1316561B1 (fr)
JP (1) JP4035400B2 (fr)
KR (1) KR100467751B1 (fr)
CN (1) CN100400548C (fr)
AT (1) ATE352565T1 (fr)
AU (1) AU2002300734B2 (fr)
BR (1) BR0203386A (fr)
CA (1) CA2400908C (fr)
DE (1) DE60217804T2 (fr)
ES (1) ES2280487T3 (fr)
MX (1) MXPA02008454A (fr)
NZ (1) NZ520776A (fr)
RU (1) RU2232192C2 (fr)
TW (1) TWI243827B (fr)
WO (1) WO2003048210A1 (fr)
ZA (1) ZA200206879B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
BRPI0414887A (pt) * 2003-09-29 2006-12-12 Warren Pharmaceuticals Inc E T métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
CN100516225C (zh) * 2004-07-30 2009-07-22 成都地奥制药集团有限公司 人血清蛋白与促红细胞生成素的融合蛋白
ES2550055T3 (es) * 2005-08-05 2015-11-04 Araim Pharmaceuticals, Inc. Péptidos protectores de tejido y usos de los mismos
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
CN100436482C (zh) * 2006-04-14 2008-11-26 东莞太力生物工程有限公司 长效人促红细胞生成素融合蛋白及其制备和纯化方法
US8067548B2 (en) 2007-07-26 2011-11-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CN102994547B (zh) * 2011-09-08 2015-05-13 哈药集团技术中心 重组人促红素-ctp融合蛋白生产工艺及应用
CN103182073A (zh) * 2011-12-29 2013-07-03 哈药集团技术中心 一种重组人干扰素α-CTP融合蛋白的药物注射剂
CN104487082A (zh) 2012-04-19 2015-04-01 奥普科生物制品有限公司 长效胃泌酸调节素变体及其生产方法
BR122020018510B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia
WO2014159813A1 (fr) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Molécules polynucléotidiques à longue durée de vie
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN107438623B (zh) * 2014-12-10 2023-07-14 Opko生物科学有限公司 长效的ctp修饰的生长激素多肽的制备方法
WO2016203482A2 (fr) 2015-06-19 2016-12-22 Opko Biologics Ltd. Facteurs de coagulation à action prolongée et leurs procédés de production
HUE064463T2 (hu) 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
CN110393801A (zh) * 2018-04-24 2019-11-01 中国科学院上海生命科学研究院 靶向促黄体生成素促进机体造血的应用
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU648020B2 (en) * 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
ES2141229T3 (es) * 1993-04-20 2000-03-16 Univ Washington Productos farmaceuticos de proteinas y peptidos modificados.
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
NZ517184A (en) 1999-07-13 2004-02-27 Bolder Biotechnology Inc Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
EP1342730B1 (fr) 2000-12-11 2006-03-15 Cheil Jedang Corporation Proteine de fusion presentant une activite i in vivo /i amelioree d'erythropoietine

Also Published As

Publication number Publication date
CA2400908A1 (fr) 2003-06-03
CN100400548C (zh) 2008-07-09
RU2232192C2 (ru) 2004-07-10
MXPA02008454A (es) 2005-08-26
AU2002300734B2 (en) 2009-01-08
US7091326B2 (en) 2006-08-15
KR20030045341A (ko) 2003-06-11
KR100467751B1 (ko) 2005-01-24
CA2400908C (fr) 2011-04-12
ATE352565T1 (de) 2007-02-15
ES2280487T3 (es) 2007-09-16
NZ520776A (en) 2004-02-27
DE60217804D1 (de) 2007-03-15
JP4035400B2 (ja) 2008-01-23
CN1422870A (zh) 2003-06-11
JP2003189853A (ja) 2003-07-08
EP1316561B1 (fr) 2007-01-24
US20030113871A1 (en) 2003-06-19
EP1316561A1 (fr) 2003-06-04
TWI243827B (en) 2005-11-21
BR0203386A (pt) 2004-05-25
DE60217804T2 (de) 2007-09-13
WO2003048210A1 (fr) 2003-06-12

Similar Documents

Publication Publication Date Title
ZA200206879B (en) Fusion protein having enhanced in vivo erythropoietin activity.
AU2002222740A1 (en) Fusion protein having the enhanced in vivo activity of erythropoietin
EP2557160A3 (fr) D-aminotransférase mutée et procédé de production de dérivés dýacide glutamique optiquement actif lýutilisant
NZ517012A (en) Peptides that lower blood glucose levels
AU4003999A (en) Healthbar formulations
CA2423887A1 (fr) Desoxynucleotidyl-transferase terminale recombinante possedant une fonctionnalite superieure
EP1449918A4 (fr) Procede de production de l-aminoacides a l'aide d'escherichia
GB9927603D0 (en) Use of a milk protein hydrolysate in the treatment of diabetes
SI1077692T1 (en) Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same
HK1049429A1 (en) Infant formula with improved protein content.
HK1026215A1 (en) Analogs of parathyroid hormone
RU2002123286A (ru) Слитый белок с увеличенной эритропоэтиновой активностью, нуклеиновая кислота, кодирующая слитый белок, и способ получения слитого белка
EP1319712A3 (fr) Protéine de fusion ayant une activité d'erythropoietine améliorée
MXPA04004848A (es) Dispositivo para conectar un soporte longitudinal con un medio de fijacion osea.
EP1188826A3 (fr) Hydantoine racemase substitue en position 5, ADN codant cet enzyme, et procédé d'elaboration d'aminoacides optiquement actifs
ZA200200128B (en) Novel naphtylsulfonic acids and related compounds as glucose uptake agonists.
EE200000487A (et) Kaspaas-8 proteaasiga interakteeruv proteiin, seda kodeeriv DNA järjestus, selle valmistamis- ja identifitseerimismeetod ning kasutamine ravimi valmistamiseks
AU4964197A (en) Recombinant single-stranded equine chorionic gonadotropin
WO1999051740A3 (fr) Sequence de nucleotides exprimant la proteine humaine de transport d'acides gras et sequence correspondante d'acides amines. utilisation pour reguler le metabolisme des acides gras
ES2115543A1 (es) Procedimiento para la obtencion de carbetocina y sus sales de adicion de acido farmaceuticamente aceptables o complejos de la misma.
AU2003271452A1 (en) Modified glp-1 peptides with increased biological potency
EP1056731A4 (fr) Derives aminoacides de diaryl 1,3,4-oxadiazolone
Stolyarov et al. Analog of Helman-Feynman theorem in multichannel theory of quantum defect; Analog teoremy Gel'mana-Fejnmana v mnogokanal'noj teorii kvantovogo defekta
ZA991107B (en) Process for preparing 3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino] benzoic acid.
AU1006601A (en) Toothbrush